KEY POINTS
- This nationwide retrospective cohort study used the Netherlands Cancer Registry to identify patients with cTanyN3M0 esophageal or gastroesophageal junction cancer diagnosed between 2015 and 2022. Among 19,867 patients with esophageal cancer, only 316 (1.6%) had clinical N3M0 disease, and 265 met the inclusion criteria. Treatment strategies included neoadjuvant chemoradiotherapy intended for surgery (n=134), definitive chemoradiotherapy (n=59), induction or perioperative chemotherapy (n=11), and palliative treatment (n=61).
- The principal comparison involved treatment strategies initiated, not surgery actually received. Neoadjuvant chemoradiotherapy generally consisted of 41.4 Gy in 23 fractions with weekly carboplatin and paclitaxel, whereas definitive chemoradiotherapy commonly delivered 50.4 Gy in 28 fractions with the same chemotherapy combination. Esophagectomy was ultimately performed in 92/134 patients (68.6%) in the neoadjuvant group and 3/59 (5.1%) in the definitive group. Adjuvant nivolumab was administered to only 14 patients (10.4%) and one patient (1.7%), respectively.
- Neoadjuvant chemoradiotherapy was not associated with significantly longer overall survival in the unmatched analysis. Median OS was 18.8 months after neoadjuvant treatment versus 15.2 months after definitive chemoradiotherapy (HR 0.76, 95% CI 0.54–1.08). Patients receiving induction or perioperative chemotherapy had median OS of 18.9 months, while those receiving palliative treatment had median OS of 7.1 months. These latter groups were small or clinically different and were not included in adjusted comparisons.
- Propensity score matching did not establish a survival advantage for the surgery-intended strategy. After matching on demographic, clinical, tumor, and treatment-era characteristics, 38 patients per group remained. Median OS was 17.6 months with neoadjuvant versus 16.1 months with definitive chemoradiotherapy (HR 0.78, 95% CI 0.46–1.31). The proportional-hazards assumption was violated in the matched analysis (p=0.026), but restricted mean survival-time analyses at 36, 48, and 60 months also found no statistically significant differences. At 36 months, the estimated survival-time difference was +0.2 months (95% CI −5.2 to 5.7).
- Distant progression dominated recurrence patterns after curative-intent treatment. Among 97 patients diagnosed in 2015–2018 with available recurrence data, 65 (67%) developed a documented first recurrence, of which approximately 85% involved distant metastases rather than isolated locoregional failure. One-year progression-free survival was 50.2% after neoadjuvant versus 55.8% after definitive chemoradiotherapy (HR 1.15, 95% CI 0.65–2.02). These findings suggest that systemic disease control is a major limitation even when aggressive local treatment is pursued.
- Only a small proportion achieved long-term survival despite curative-intent treatment. The authors reported approximately 8% five-year survival in the cN3M0 population treated with curative intent. Importantly, the neoadjuvant and definitive groups differed substantially before matching: 82.8% versus 42.4% had adenocarcinoma, and patients receiving neoadjuvant therapy were generally younger, fitter, and less likely to have T4 disease. Matching improved comparability but excluded cT4b disease and substantially reduced the evaluable population.
- The findings cannot establish that esophagectomy is unnecessary in clinical N3 disease. Treatment groups were reconstructed mainly from radiation dose and surgery records, rather than prospectively recorded treatment intentions, and the study lacked data on frailty, patient preference, nodal burden distribution, and nutritional status. The matched cohort contained only 76 patients, with wide confidence intervals and residual imbalances. Furthermore, recurrence assessment was not systematic, and contemporary FLOT-based strategies and immunotherapy were insufficiently represented.
CLINICAL TAKEAWAY
Among patients with extensive regional nodal involvement from esophageal cancer, a surgery-intended neoadjuvant chemoradiotherapy strategy was not associated with a statistically significant survival advantage over definitive chemoradiotherapy in this nationwide observational study. The high proportion of distant recurrences emphasizes the importance of systemic disease control and careful selection for intensive local treatment. These data do not demonstrate treatment equivalence or justify routinely omitting surgery in otherwise suitable patients.